European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. / Sorbye, Halfdan; Grande, Enrique; Pavel, Marianne; Tesselaar, Margot; Fazio, Nicola; Reed, Nicholas Simon; Knigge, Ulrich; Christ, Emanuel; Ambrosini, Valentina; Couvelard, Anne; Tiensuu Janson, Eva.
In: Journal of Neuroendocrinology, Vol. 35, No. 3, e13249, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
AU - Sorbye, Halfdan
AU - Grande, Enrique
AU - Pavel, Marianne
AU - Tesselaar, Margot
AU - Fazio, Nicola
AU - Reed, Nicholas Simon
AU - Knigge, Ulrich
AU - Christ, Emanuel
AU - Ambrosini, Valentina
AU - Couvelard, Anne
AU - Tiensuu Janson, Eva
N1 - Publisher Copyright: © 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
PY - 2023
Y1 - 2023
N2 - This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. These recommendations aim to pave the road for more standardized care for our patients resulting in improved outcomes. Prognosis is generally poor for digestive NEC, most are advanced at diagnosis and median survival in metastatic disease is 11–12 months. Surgery can be of benefit for localized disease after extensive preoperative imaging. Carboplatin in combination with etoposide is recommended as first-line treatment for metastatic disease. Irinotecan with fluoropyrimidines has the best evidence as second-line treatment. Immunotherapy plays a minor role in biomarker-unselected patients. Molecular profiling if available is encouraged to identify new targets. More prospective clinical trials are highly needed to fulfil the unmet needs in this field, especially on new predictive and prognostic biomarkers and to improve survival of patients with advanced disease.
AB - This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. These recommendations aim to pave the road for more standardized care for our patients resulting in improved outcomes. Prognosis is generally poor for digestive NEC, most are advanced at diagnosis and median survival in metastatic disease is 11–12 months. Surgery can be of benefit for localized disease after extensive preoperative imaging. Carboplatin in combination with etoposide is recommended as first-line treatment for metastatic disease. Irinotecan with fluoropyrimidines has the best evidence as second-line treatment. Immunotherapy plays a minor role in biomarker-unselected patients. Molecular profiling if available is encouraged to identify new targets. More prospective clinical trials are highly needed to fulfil the unmet needs in this field, especially on new predictive and prognostic biomarkers and to improve survival of patients with advanced disease.
KW - diagnosis
KW - digestive
KW - NEC
KW - neuroendocrine carcinoma
KW - neuroendocrine neoplasms
U2 - 10.1111/jne.13249
DO - 10.1111/jne.13249
M3 - Journal article
C2 - 36924180
AN - SCOPUS:85150772590
VL - 35
JO - Journal of Neuroendocrinology
JF - Journal of Neuroendocrinology
SN - 0953-8194
IS - 3
M1 - e13249
ER -
ID: 360067968